AIM ImmunoTech furnishes January 2026 corporate presentation

AIM ImmunoTech Inc.

Presentation filed as Exhibit 99.1 on Form 8-K dated January 12, 2026.
No financial results or operational milestones disclosed in the filing.
Cautionary statements reiterate risks of Ampligen development across viral, cancer, and immune indications.

item 7.01 item 9.01

AIM ImmunoTech Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-001898

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.